<DOC>
	<DOCNO>NCT00005854</DOCNO>
	<brief_summary>RATIONALE : Bone marrow transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill tumor cell . PURPOSE : Phase II trial study effectiveness bone marrow transplantation treat patient hematologic cancer .</brief_summary>
	<brief_title>Bone Marrow Transplantation Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine incidence severity acute graft versus host disease transplantation HLA haploidentical bone marrow preincubated alloantigen CTLA4-Ig ex vivo patient hematologic malignancy . II . Determine engraftment rate treatment regimen patient . III . Determine safety treatment regimen patient . IV . Determine incidence infection relapse treatment regimen patient . V. Determine whether host specific tolerance develop patient receive treatment regimen . OUTLINE : This multicenter study . Patients undergo leukapheresis collect white blood cell incubate donor bone marrow cell presence CTLA4-Ig 36 hour . Patients undergo total body irradiation day -7 , -6 , -5 , -4 receive cyclophosphamide IV day -3 -2 . Patients acute lymphocytic leukemia , prior lymphoid blast crisis chronic myelogenous leukemia , high grade non-Hodgkin 's leukemia ( NHL ) , intermediate grade NHL prior marrow extramedullary disease , prior CNS leukemia receive 2 dos methotrexate intrathecally prior bone marrow transplantation , 4-6 dos follow . Patients receive bone marrow transplantation day 0 ; methotrexate IV day 1 , 3 , 6 , 11 ; cyclosporine IV day -1 50 . Patients follow weekly 1 month , monthly 2 year , annually thereafter . PROJECTED ACCRUAL : A total 30 patient accrue study 1-2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Any follow hematologic malignancy : Acute myelogenous leukemia second great remission relapse High risk acute lymphoblastic leukemia First complete remission high risk cytogenetics [ e.g. , ( 9 ; 22 ) , ( 8 ; 14 ) , ( 4 ; 11 ) ] slow early response OR Any second great remission OR Relapse induction failure Relapsed nonHodgkin 's lymphoma ( NHL ) chemotherapy sensitive disease Multiple myeloma chemotherapy sensitive disease Chronic lymphocytic leukemia chemotherapy sensitive disease Myelodysplastic syndrome Chronic myelogenous leukemia ( CML ) accelerate phase , blast phase , remission blast phase Juvenile CML Patients must haploidentical donor meet follow criterion : Lack HLA A , B , DR match related donor Lack HLA A , B , DRB1 match single allele mismatch unrelated donor follow apply : High likelihood rapid disease progression unrelated donor search progress AND Review patient HLA typing , gene frequency , result preliminary search donor pool suggest donor find within suitable time frame Lack HLA A , B , DRB1 match cord blood unit lack cord blood unit adequate cell dose mismatch 12 HLA A , B , DRB1 Do indication autologous transplant , include patient NHL multiple myeloma eligible autologous transplant Negative antidonor antibody crossmatch PATIENT CHARACTERISTICS : Age : Under 51 Performance status : Not specify Life expectancy : No patient life expectancy severely limited disease malignancy Hematopoietic : See Disease Characteristics Hepatic : AST great 2 time normal Renal : Creatinine great 2 time normal OR Creatinine clearance least 50 % age , weight , height Cardiovascular : No cardiac insufficiency require treatment No symptomatic coronary artery disease Pulmonary : No severe hypoxemia pO2 le 70 mm Hg decrease DLCO le 70 % predict OR No mild hypoxemia pO2 le 80 mm Hg severely decrease DLCO le 60 % predict Other : HIV negative Not pregnant nurse Fertile patient must use effective contraception one year study No leukoencephalopathy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No 3,000 cGy prior radiotherapy brain No 1,500 cGy prior radiotherapy chest abdomen Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>